Icariside II in NSCLC and COVID‐19: Network pharmacology and molecular docking study
Qing Kong,
Huahe Zhu,
Jingcheng Dong
et al.
Abstract:BackgroundPatients with non‐small cell lung cancer (NSCLC) are susceptible to coronavirus disease‐2019 (COVID‐19), but current treatments are limited. Icariside II (IS), a flavonoid compound derived from the plant epimedin, showed anti‐cancer,anti‐inflammation and immunoregulation effects. The present study aimed to evaluate the possible effect and underlying mechanisms of IS on NSCLC patients with COVID‐19 (NSCLC/COVID‐19).MethodsNSCLC/COVID‐19 targets were defined as the common targets of NSCLC (collected fr… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.